Nine Ten Capital Management’s Utah Medical Products UTMD Stock Holding History

Nine Ten Capital Management’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-59,371	Closed	-$3.7M	–	10
2017 Q1	$3.7M	Sell	59,371 -57,573	-49%	-$3.62M	1.08%	10
2016 Q4	$8.51M	Sell	116,944 -100,008	-46%	-$6.5M	2.5%	10
2016 Q3	$13M	Sell	216,952 -28,532	-12%	-$1.82M	4.48%	8
2016 Q2	$15.5M	Sell	245,484 -25,655	-9%	-$1.65M	5.72%	8
2016 Q1	$17M	Hold	271,139	–	–	6.48%	8
2015 Q4	$15.9M	Hold	271,139	–	–	6.83%	8
2015 Q3	$14.6M	Hold	271,139	–	–	6.57%	8
2015 Q2	$16.2M	Hold	271,139	–	–	5.71%	9
2015 Q1	$16.2M	Buy	+271,139	New	+$15.9M	5.32%	8

Other funds holding UTMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Nine Ten Capital Management's UTMD Position: Q2 2017 in Review

Nine Ten Capital Management sold out of Utah Medical Products (UTMD) in Q2 2017, closing a stake of 59,371 shares — an estimated $3.7M sold.

Nine Ten Capital Management first reported a position in UTMD in Q1 2015 and held it in 9 quarters. The position peaked at $17M in Q1 2016. 76 funds tracked by Wall St. Rank hold UTMD as of Q2 2017.

Nine Ten Capital Management reported no remaining Utah Medical Products position as of Q2 2017 after selling out during the quarter.
Nine Ten Capital Management sold 59,371 Utah Medical Products shares in Q2 2017, an estimated $3.7M.
Nine Ten Capital Management first reported a position in Utah Medical Products in Q1 2015 and held it in 9 quarters.
Nine Ten Capital Management's Utah Medical Products position peaked at $17M in Q1 2016.
76 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2017.

Based on Nine Ten Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.